LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

30.95 0.88

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.51

Max

31.63

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	186
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+78.65% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	377M 2B
Vorige openingsprijs	30.07
Vorige sluitingsprijs	30.95

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2026, 20:38 UTC

Winsten

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mrt 2026, 23:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

10 mrt 2026, 23:57 UTC

Marktinformatie

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mrt 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mrt 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mrt 2026, 23:35 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mrt 2026, 23:06 UTC

Winsten

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mrt 2026, 22:51 UTC

Belangrijke Nieuwsgebeurtenissen

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mrt 2026, 21:21 UTC

Winsten

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mrt 2026, 21:15 UTC

Winsten

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mrt 2026, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mrt 2026, 21:14 UTC

Winsten

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mrt 2026, 21:13 UTC

Winsten

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mrt 2026, 21:12 UTC

Winsten

Franco-Nevada 4Q Rev $597.3M >FNV

10 mrt 2026, 21:12 UTC

Winsten

Franco-Nevada 4Q EPS $1.90

10 mrt 2026, 20:57 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

10 mrt 2026, 20:44 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:34 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

10 mrt 2026, 20:34 UTC

Marktinformatie

Winsten

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mrt 2026, 20:23 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mrt 2026, 20:16 UTC

Winsten

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mrt 2026, 20:14 UTC

Winsten

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mrt 2026, 20:14 UTC

Winsten

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mrt 2026, 20:13 UTC

Winsten

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mrt 2026, 20:12 UTC

Winsten

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

78.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.9 USD 78.65%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.